DOSING & ADMINISTRATION

CONVENIENT, ONCE-DAILY DOSING AND CUSTOMIZABLE ADMINISTRATION¹

Hypothetical patient portrayal. Individual results may vary.

7 Capsule Strengths^*1

10 mg

TITRATION
STRENGTHS

20 mg

30 mg

RECOMMENDED
STARTING DOSE

40 mg

50 mg

60 mg

70 mg

MAXIMUM
DAILY DOSE

*The amount of powder in a Vyvanse capsule varies by capsule strength.²

Capsules not shown at actual size.

7 Capsule Strengths^*1

10 mg

20 mg

TITRATION
STRENGTHS

30 mg

RECOMMENDED
STARTING DOSE

40 mg

50 mg

60 mg

70 mg

MAXIMUM
DAILY
DOSE

*The amount of powder in a Vyvanse capsule varies by capsule strength.
Capsules not shown at actual size.

6 Chewable Strengths¹

10 mg

20 mg

TITRATION STRENGTHS

30 mg

RECOMMENDED
STARTING DOSE

40 mg

50 mg

60 mg

Chewable tablets not shown at actual size.

6 Chewable Strengths¹

10 mg

TITRATION
STRENGTHS

20 mg

30 mg

RECOMMENDED
STARTING DOSE

40 mg

50 mg

60 mg

Chewable tablets not shown at actual size.

Vyvanse recommended starting dose: 30 mg once daily in the morning. Avoid afternoon doses due to the potential for insomnia¹
Dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals¹
Vyvanse 10 mg is the lowest strength available for patients who may need flexible titration¹
Maximum dose: 70 mg per day¹
May be taken with or without food¹
Capsules and chewable tablets are interchangeable on a unit-per-unit/mg-per-mg basis (eg, 30 mg capsule for 30 mg chewable tablet)¹

DOSING SAFETY INFORMATION

Severe renal impairment: maximum dose should not exceed 50 mg/day; end stage renal disease: maximum recommended dose of 30 mg/day¹
Prior to treatment, assess for cardiac disease; after prescribing, keep prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and reevaluate the need for Vyvanse use¹

Child drinking orange juice, a mixable option to administer Vyvanse® (lisdexamfetamine dimesylate).

Hypothetical patient portrayal.
Individual results may vary.

Only Vyvanse offers 5 administration options¹

Tailor treatment to meet the needs of your appropriate adult and pediatric patients with ADHD.

Chewable¹

Vyvanse® (lisdexamfetamine dimesylate) is available as a chewable option.

TO ADMINISTER:

Chewable tablet must be chewed thoroughly before swallowing
Take entire chewable tablet daily (do not divide dose)

Mixable¹

Vyvanse® (lisdexamfetamine dimesylate) capsules may be swallowed whole or mixed in orange juice, yogurt, or water.

with orange juice, yogurt or water

TO ADMINISTER:

Open capsule and mix contents in orange juice, water, or yogurt until completely dispersed
Stir to break apart any compacted powder
Consume immediately (do not store)
Take full contents of capsule daily (do not divide dose)

Swallowable¹

Vyvanse® (lisdexamfetamine dimesylate) is available as a swallowable option.

TO ADMINISTER:

Swallow whole
Take capsule daily (do not divide dose)

Capsules and chewable tablets not shown at actual size.

ADULT ADHD EDUCATION
BROCHURE FOR PATIENTS

Offer this brochure to your appropriate
patients with ADHD considering their
treatment options.

Download Adult ADHD Brochure

Vyvanse® caregivers brochure for ADHD in children.

ADHD IN CHILDREN AND ADOLESCENTS
EDUCATION BROCHURE FOR CAREGIVERS

Caregivers need support too. Offer this
brochure to caregivers of children with ADHD
considering their treatment options.

Download ADHD Caregiver Brochure

Hypothetical patient portrayal

KEEP IN TOUCH

Stay up to date with the latest information and resources to help support your Vyvanse patients.

References

Vyvanse [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.
Data on file; SPD489-166; Shire US Inc.

INDICATION AND LIMITATIONS OF USE

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 and older. Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Contraindications
- Known hypersensitivity to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
- Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
Warnings and Precautions
- Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in pediatric patients with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
- CNS stimulants cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
- Exacerbation of Pre-existing Psychosis: May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, and depression). New Psychotic or Manic Symptoms: At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients with no prior history of psychotic illness or mania. Discontinue if symptoms occur.
- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients (monitor weight and height). Treatment may need to be interrupted in patients not growing or gaining weight as expected. Vyvanse is not approved for use in pediatric patients below 6 years of age.
- CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with stimulants. Further evaluation may be required, including referral.
- Increased risk of serotonin syndrome when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans) and CYP2D6 inhibitors, but also during overdosage situations. Discontinue Vyvanse if it occurs and initiate supportive treatment.
Adverse Reactions
- Children aged 6 to 12: decreased appetite, insomnia, upper abdominal pain, irritability, vomiting, decreased weight, nausea, dry mouth, and dizziness;
- Adolescents aged 13 to 17: decreased appetite, insomnia, and decreased weight;
- Adults: decreased appetite, insomnia, dry mouth, diarrhea, nausea, anxiety, and anorexia.
Pregnancy and Lactation

Please click here for Full Prescribing Information.

VYVANSE and the VYVANSE logo are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. ©2022 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327).

All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda Pharmaceuticals U.S.A., Inc. and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or, distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Terms of Use for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US healthcare professional.

US-LIS-1285v1.0 10/22

Keep in touch

INDICATION AND LIMITATIONS OF USE

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in ages 6+. Pediatric patients with ADHD <6 years of age experienced more long-term weight loss than patients 6+ years. It is not for weight loss or to treat obesity. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. Click here for FULL SAFETY INFORMATION.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE: CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Click here for FULL SAFETY INFORMATION.

INDICATION AND IMPORTANT SAFETY INFORMATION

Go Back

INDICATION AND LIMITATIONS OF USE

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Vyvanse, other amphetamine-containing products, and methylphenidate have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Contraindications
- Known hypersensitivity to amphetamines or other ingredients of Vyvanse. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have occurred.
- Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis.
Warnings and Precautions
- Prior to and during treatment assess for the presence of cardiac disease. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in pediatric patients with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias while taking Vyvanse.
- CNS stimulants cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
- Exacerbation of Pre-existing Psychosis: May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, and depression). New Psychotic or Manic Symptoms: At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients with no prior history of psychotic illness or mania. Discontinue if symptoms occur.
- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients (monitor weight and height). Treatment may need to be interrupted in patients not growing or gaining weight as expected. Vyvanse is not approved for use in pediatric patients below 6 years of age.
- CNS stimulants, including Vyvanse, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with stimulants. Further evaluation may be required, including referral.
- Increased risk of serotonin syndrome when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans) and CYP2D6 inhibitors, but also during overdosage situations. Discontinue Vyvanse if it occurs and initiate supportive treatment.
Adverse Reactions
- Children aged 6 to 12: decreased appetite, insomnia, upper abdominal pain, irritability, vomiting, decreased weight, nausea, dry mouth, and dizziness;
- Adolescents aged 13 to 17: decreased appetite, insomnia, and decreased weight;
- Adults: decreased appetite, insomnia, dry mouth, diarrhea, nausea, anxiety, and anorexia.
Pregnancy and Lactation
Vyvanse may cause fetal harm. Breastfeeding is not recommended during Vyvanse treatment.

DOSING & ADMINISTRATION

CONVENIENT, ONCE-DAILY DOSING AND CUSTOMIZABLE ADMINISTRATION1

7 Capsule Strengths*1

7 Capsule Strengths*1

6 Chewable Strengths1

6 Chewable Strengths1

DOSING SAFETY INFORMATION

Only Vyvanse offers 5 administration options1

Tailor treatment to meet the needs of your appropriate adult and pediatric patients with ADHD.

Chewable1

TO ADMINISTER:

Mixable1

TO ADMINISTER:

Swallowable1

TO ADMINISTER:

ADULT ADHD EDUCATION BROCHURE FOR PATIENTS

ADHD IN CHILDREN AND ADOLESCENTS EDUCATION BROCHURE FOR CAREGIVERS

KEEP IN TOUCH

References

INDICATION AND IMPORTANT SAFETY INFORMATION

CONVENIENT, ONCE-DAILY DOSING AND CUSTOMIZABLE ADMINISTRATION¹

7 Capsule Strengths^*1

7 Capsule Strengths^*1

6 Chewable Strengths¹

6 Chewable Strengths¹

Only Vyvanse offers 5 administration options¹

Chewable¹

Mixable¹

Swallowable¹

ADULT ADHD EDUCATION
BROCHURE FOR PATIENTS

ADHD IN CHILDREN AND ADOLESCENTS
EDUCATION BROCHURE FOR CAREGIVERS